A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
A user shared their experience with a hair transplant, emphasizing the importance of avoiding caffeine 7 days before the procedure. Ignoring this advice led to reduced effectiveness of the numbing agent, causing significant discomfort during the transplant.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
The conversation is about compounding topical cyclosporine for hair loss, suggesting it needs an oil base like castor oil. The user seeks tips or tricks for the process.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
The user has been using a combination of finasteride/dutasteride, minoxidil, tretinoin, and hydrocortisone with microneedling and ketoconazole shampoo for hair loss. They are asking if the baby hairs growing will turn into terminal hairs with continued treatment.
User shows temple area progress after hair transplant, using DUT every other day and oral Min 2.5 daily. Another user asks about number of grafts and cost.
Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.
The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.
A 22-year-old with 4c hair is considering a hair transplant to address traction alopecia caused by braid extensions. They have tried derma stamping, oils, and minoxidil but stopped due to side effects.